Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Pain, Neuropathic: full-pipeline trial registry

4 of 6 indexed Pain, Neuropathic trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Pain, Neuropathic: 6 US clinical trials tracked, 4 recruiting.

Pain, Neuropathic is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ashwin Viswanathan, running 1 of these trials.

Enrollment posture brief

Registry condition pain-neuropathic

OPEN 4 | RECR 67% | LATE 1 | EARLY 1 | RANK #2866 | SPON 1

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Pain, Neuropathic (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Pain, Neuropathic

Pain, Neuropathic lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pain, Neuropathic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pain, Neuropathic is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pain, Neuropathic research.

    Ashwin Viswanathan accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Pain, Neuropathic trials plan to enrol fewer than 100 people.

    Median target enrolment is 44 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Pain, Neuropathic research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 4 1

Named interventions

Most-linked intervention names on Pain, Neuropathic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bupivacaine/epinephrine/dexamethasone Drug
1 trials
Placebo Moxibustion Other
1 trials
Moxibustion - Smokeless - (Active) Other
1 trials
Moxibustion - Traditional (Active) Other
1 trials
Spinal Cord Stimulator Device
1 trials
(2R,6R)-hydroxynorketamine Drug
1 trials
TENS treatment Device
1 trials
Scrambler therapy Device
1 trials

US sites by state

Facility locations filed on Pain, Neuropathic trials. A trial with sites in several states counts in each.

Illinois 2 trials
Texas 1 trials
New York 1 trials
Michigan 1 trials
Maryland 1 trials
Massachusetts 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pain, Neuropathic page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pain, Neuropathic condition card totals 6 registered trials; most-linked intervention Bupivacaine/epinephrine/dexamethasone; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.